Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Neurofilaments As Serum Biomarkers of Brentuximabvedotin-Induced Peripheral Neurotoxicity in CD30 + Lymphoma Patients: A Prospective Single-Center Study

Eva Domingo Domenech, Carla Marco, Eva Maria Gonzalez Barca, Cristina Muniesa, Patricia Lopez-Pereira, Ana C. De Oliveira, Carmen Aguilera, German Ferrer, Anna Maria Sureda Balari, Roser Velasco

Blood (2023) 142 (Supplement 1): 6186.

https://doi.org/10.1182/blood-2023-182348

Published: 2023

Journal Articles

PET4 Response As an Independent Predictor of Long-Term Outcomes in ECHELON2 (A+CHP Vs. CHOP) in CD30+PTCL

Blood (2023) 142 (Supplement 1): 3074.

https://doi.org/10.1182/blood-2023-184933

Published: 2023

Journal Articles

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early-Stage Classical Hodgkin Lymphoma (SGN35-027 Part C)

Blood (2023) 142 (Supplement 1): 611.

https://doi.org/10.1182/blood-2023-172574

Published: 2023

Journal Articles

Efficacy and Safety of Valemetostat Monotherapy in Patients with Relapsed or Refractory Peripheral T-Cell Lymphomas: Primary Results of the Phase 2 VALENTINE-PTCL01 Study

Blood (2023) 142 (Supplement 1): 302.

https://doi.org/10.1182/blood-2023-179304

Published: 2023

Journal Articles

Comprehensive Geriatric Assessment in Diffuse Large B-Cell Lymphomas Patients Older Than 70 Years Old: Prospective Single-Center Experience

Nicolo Rampi, Maite Antonio, Eva Domingo Domenech, Patricia Lopez-Pereira, Ana C. De Oliveira, Carmen Aguilera, Anna Maria Sureda Balari, Eva Maria Gonzalez Barca

Blood (2023) 142 (Supplement 1): 6280.

https://doi.org/10.1182/blood-2023-190136

Published: 2023

Journal Articles

Impact of Front-Line Treatment Interim PET/CT in Peripheral T-Cell Lymphoma Patients' Survival: Experience of a Single Center

Nicolo Rampi, Montserrat Cortes-Romera, Patricia Lopez-Pereira, Carolina Martinez-Ramos, Clara Montane Carbo, Carolina Esther Arevalo Leon, Ana C. De Oliveira, Eva Maria Gonzalez Barca, Anna Maria Sureda Balari, Eva Domingo Domenech

Blood (2023) 142 (Supplement 1): 6216.

https://doi.org/10.1182/blood-2023-186195

Published: 2023

Journal Articles

Epigenetic loss of m 1 A RNA demethylase ALKBH3 in Hodgkin lymphoma targets collagen, conferring poor clinical outcome

Blood (2021) 137 (7): 994–999.

https://doi.org/10.1182/blood.2020005823

Published: 2021

Includes: Supplemental data

Journal Articles

A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma

Nancy L. Bartlett, Alex F. Herrera, Eva Domingo-Domenech, Amitkumar Mehta, Andres Forero-Torres, Ramon Garcia-Sanz, Philippe Armand, Sumana Devata, Antonia Rodriguez Izquierdo, Izidore S. Lossos, Craig Reeder, Taimur Sher, Robert Chen, Sylvia E. Schwarz, Leila Alland, Andras Strassz, Kim Prier, Cassandra Choe-Juliak, Stephen M. Ansell

Blood (2020) 136 (21): 2401–2409.

https://doi.org/10.1182/blood.2019004701

Published: 2020

Includes: Supplemental data

Journal Articles

The Echelon-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma

Blood (2020) 136 (Supplement 1): 3–5.

https://doi.org/10.1182/blood-2020-134398

Published: 2020

Journal Articles

Impact of a Tailored Nutritional and Physical Exercise Programme on Efficacy and Functional Outcomes in Older Patients with Hematological Malignancies Classified By Frailty Profile

Maite Antonio, MD PhD, Montserrat Arnan Sangerman, MD PhD, Eva Domingo-Domenech, MD, Eva González-Barca, MD PhD, Casimiro Javierre, MD PhD, Laura Hurtos, Judit Sola, Anna Sureda, MD PhD, Josep Maria Borras, MD PhD

Blood (2019) 134 (Supplement_1): 3424.

https://doi.org/10.1182/blood-2019-129908

Published: 2019

Journal Articles

An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Consolidative Stem Cell Transplant

Blood (2019) 134 (Supplement_1): 464.

https://doi.org/10.1182/blood-2019-122781

Published: 2019

Journal Articles

Proof of Concept for Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study

Blood (2019) 134 (Supplement_1): 468.

https://doi.org/10.1182/blood-2019-128513

Published: 2019

Journal Articles

Analysis of the Different Surveillance Strategies for Patients with Hodgkin Lymphoma in Clinical Remission after First-Line Treatment. a Study of the Geltamo Group (Spanish lymphoma and autologous transplant group)

Mariana Bastos-Oreiro, MD PhD, Nieves Lopez, Pilar Gomez, Liébana Marta, Laura LLorente, MD, Antonio Gutiérrez, EVA Domingo Domenech, PhD, Maria Jesus Vidal Maceñido, MD, Raquel Del Campo, Leyre Bento, Daniel Garcia, Miriam Santero, Jaime Perez De Oteyza, MD PhD, Belén Navarro, MD, Antonia Rodriguez Izquierdo, Ramón García-Sanz, MD PhD

Blood (2019) 134 (Supplement_1): 4040.

https://doi.org/10.1182/blood-2019-125813

Published: 2019

Journal Articles

The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas

Blood (2018) 132 (Supplement 1): 997.

https://doi.org/10.1182/blood-2018-99-110563

Published: 2018

Journal Articles

A Phase 1b Study Investigating the Combination of the Tetravalent Bispecific NK Cell Engager AFM13 and Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after Brentuximab Vedotin Failure: Updated Safety and Efficacy Data

Nancy L. Bartlett, MD, Robert W. Chen, MD, Eva Domingo-Domenech, MD, Andres Forero-Torres, MD, Ramon Garcia-Sanz, MD PhD, Philippe Armand, MD PhD, Sumana Devata, MD, Antonia Rodriguez Izquierdo, MD, Izidore S. Lossos, MD, Craig B. Reeder, MD, Taimur Sher, MD, Cassandra Choe-Juliak, MD MS, Kim Prier, Sylvia Schwarz, PhD, Andras Strassz, MD, Leila Alland, MD, Stephen M. Ansell, MD PhD

Blood (2018) 132 (Supplement 1): 1620.

https://doi.org/10.1182/blood-2018-99-118506

Published: 2018

Journal Articles

Nivolumab for Newly Diagnosed Advanced-Stage Classical Hodgkin Lymphoma (cHL): Results from the Phase 2 Checkmate 205 Study

Radhakrishnan Ramchandren, MD, Michelle A. Fanale, MD, Antonio Rueda, Philippe Armand, MD PhD, Marek Trněný, MD PhD, Tatyana A Feldman, MD, Stephen M Ansell, MD PhD, Mariano Provencio, MD, Ulrich Jaeger, MD, Jonathon B Cohen, MDMS, Kerry J Savage, BSc, MD MSc, Wolfgang Willenbacher, Mariana Sacchi, Anne Sumbul, Eva Domingo Domenech, MD

Blood (2017) 130 (Supplement 1): 651.

https://doi.org/10.1182/blood.V130.Suppl_1.651.651

Published: 2017

Journal Articles

Validation of the NCCN-IPI and the Geltamo-IPI in a Large Cohort of Patients Diagnosed of Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP/R-CHOP-like in a Single Institution

Maria Queralt Salas Gay, MD, Santiago Mercadal, MD, Eva Domingo Domenech, MD, Ana C Oliveira, MD PhD, Maite Encuentra, Fina Climent, MD PhD, Cristina Baca Cano, MD, Marcio Andrade-Campos, MD PhD, Esmeralda De la Banda, MD, Carmen Aguilera, Alberto Fernandez de Sevilla, MD PhD, Anna Sureda, Eva González-Barca, MD PhD

Blood (2017) 130 (Supplement 1): 4151.

https://doi.org/10.1182/blood.V130.Suppl_1.4151.4151

Published: 2017

Journal Articles

Long-Term Follow-up of a Prospective Phase II Trial of Extended Treatment with Rituximab in Patients with B-Cell Post-Transplant Lymphoproliferative Disease and Comparison with a Cohort of Patients Treated in Real Life. Analysis on Behalf of the Spanish Lymphoma Group (GELTAMO)

Eva Gonzalez-Barca, MD PhD, Maria Queralt Salas Gay, MD, Francisco Javier Capote Huelva, Jose Gomez Codina, Carlos Panizo, MD PhD, Antonio Salar, MD PhD, Eva Domingo Domenech, MD, Alicia Bailen, Josep-Maria Ribera, MD, Andres Lopez, Javier Briones, MD, Andres Muñoz, Maite Encuentra, Alberto Fernandez de Sevilla, MD PhD

Blood (2017) 130 (Supplement 1): 1545.

https://doi.org/10.1182/blood.V130.Suppl_1.1545.1545

Published: 2017

Journal Articles

Abnormal Karyotype (Not Only Complex) at Diagnosis Is an Independent Prognostic Factor for Overall Survival in Early Stage Chronic Lymphocytic Leukemia Patients. Results of a Prospective Study with a Median Follow-up of More Than 7-Years

Ana C Oliveira, MD PhD, Esmeralda De la Banda, MD, Eva Domingo Domenech, MD, Isabel Granada, PhD, Alberto Fernandez de Sevilla, MD PhD, Santiago Mercadal, MD, Marcio Andrade-Campos, MD PhD, Maite Encuentra, Carmen Aguilera, Anna Sureda, Eva González-Barca, MD PhD

Blood (2017) 130 (Supplement 1): 5142.

https://doi.org/10.1182/blood.V130.Suppl_1.5142.5142

Published: 2017

Journal Articles

Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma

Blood (2017) 130 (15): 1772–1774.

https://doi.org/10.1182/blood-2017-07-795302

Published: 2017

NARROW

Neurofilaments As Serum Biomarkers of Brentuximabvedotin-Induced Peripheral Neurotoxicity in CD30 + Lymphoma Patients: A Prospective Single-Center Study

PET4 Response As an Independent Predictor of Long-Term Outcomes in ECHELON2 (A+CHP Vs. CHOP) in CD30+PTCL

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early-Stage Classical Hodgkin Lymphoma (SGN35-027 Part C)

Efficacy and Safety of Valemetostat Monotherapy in Patients with Relapsed or Refractory Peripheral T-Cell Lymphomas: Primary Results of the Phase 2 VALENTINE-PTCL01 Study

Comprehensive Geriatric Assessment in Diffuse Large B-Cell Lymphomas Patients Older Than 70 Years Old: Prospective Single-Center Experience

Impact of Front-Line Treatment Interim PET/CT in Peripheral T-Cell Lymphoma Patients' Survival: Experience of a Single Center

Epigenetic loss of m 1 A RNA demethylase ALKBH3 in Hodgkin lymphoma targets collagen, conferring poor clinical outcome

A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma

The Echelon-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma

Impact of a Tailored Nutritional and Physical Exercise Programme on Efficacy and Functional Outcomes in Older Patients with Hematological Malignancies Classified By Frailty Profile

An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Consolidative Stem Cell Transplant

Proof of Concept for Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study

Analysis of the Different Surveillance Strategies for Patients with Hodgkin Lymphoma in Clinical Remission after First-Line Treatment. a Study of the Geltamo Group (Spanish lymphoma and autologous transplant group)

The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas

A Phase 1b Study Investigating the Combination of the Tetravalent Bispecific NK Cell Engager AFM13 and Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after Brentuximab Vedotin Failure: Updated Safety and Efficacy Data

Nivolumab for Newly Diagnosed Advanced-Stage Classical Hodgkin Lymphoma (cHL): Results from the Phase 2 Checkmate 205 Study

Validation of the NCCN-IPI and the Geltamo-IPI in a Large Cohort of Patients Diagnosed of Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP/R-CHOP-like in a Single Institution

Long-Term Follow-up of a Prospective Phase II Trial of Extended Treatment with Rituximab in Patients with B-Cell Post-Transplant Lymphoproliferative Disease and Comparison with a Cohort of Patients Treated in Real Life. Analysis on Behalf of the Spanish Lymphoma Group (GELTAMO)

Abnormal Karyotype (Not Only Complex) at Diagnosis Is an Independent Prognostic Factor for Overall Survival in Early Stage Chronic Lymphocytic Leukemia Patients. Results of a Prospective Study with a Median Follow-up of More Than 7-Years

Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only